BNTX250117P170000
- 62.32
- 0.000.00%
BioNTech Newsroom
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
Berenberg Bank Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $130
Truist Financial Maintains BioNTech(BNTX.US) With Buy Rating
BofA Securities Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $150
Goldman Sachs Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $137
Bank of America Securities Keeps Their Buy Rating on BioNTech SE (BNTX)
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
Truist Financial Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $172
BioNTech Analyst Ratings
Truist Financial Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $172
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Ascendis Pharma (ASND) and BioNTech SE (BNTX)
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Vertex Pharmaceuticals (VRTX) and Ascendis Pharma (ASND)
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Raises Target Price to $154.43
BioNTech SE's Strategic and Clinical Advancements Drive Buy Rating on BNT327's Promise in Oncology
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating, Announces Target Price $122
J.P. Morgan Reaffirms Their Hold Rating on BioNTech SE (BNTX)
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145